Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Bar

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Journal of the American Heart Association|May 16, 2022
Ultrashort Door-to-Needle Time for Intravenous Thrombolysis Is Safer and Improves Outcome in the Czech Republic: Nationwide Study 2004 to 2019Robert Mikulík, Michal Bar, Silvie Bělašková, et al.
Blood|January 15, 2011
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsErik A Nelson, Sarah R Walker, Ellen Weisberg, et al.
Journal of Neurology|March 25, 2011
Decompressive surgery for malignant supratentorial infarction remains underutilized after guideline publicationMichal Bar, Robert Mikulik, David Skoloudik, et al.
Genes & Cancer|December 25, 2012
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsErik A Nelson, Sarah R Walker, Michael Xiang, et al.
Circulation. Cardiovascular Quality and Outcomes|January 31, 2022
Between-Center Variation in Outcome After Endovascular Treatment of Acute Stroke: Analysis of Two Nationwide RegistriesPaula M Janssen, Katrine van Overhagen, Jan Vinklárek, et al.
Neurology. Clinical Practice|August 26, 2024
Utilization, Workflow, and Outcomes of Endovascular Thrombectomy in Patients With vs Without Premorbid Disability in a National RegistryAravind Ganesh, Ondrej Volny, Ingrid Kovacova, et al.
Biomedicines|February 24, 2024
Intravenous Thrombolysis in Posterior versus Anterior Circulation Stroke: Clinical Outcome Differs Only in Patients with Large Vessel OcclusionSimona Halúsková, Roman Herzig, Robert Mikulík, et al.
Hemasphere|March 15, 2021
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid MalignanciesJonathan Feld, Douglas Tremblay, Mikaela Dougherty, et al.
Blood|June 7, 2015
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphomaSalvia Jain, Dina Stroopinsky, Li Yin, et al.
Blood|September 17, 2014
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsRafael Bejar, Allegra Lord, Kristen Stevenson, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Journal of the American Heart Association|May 16, 2022
Ultrashort Door-to-Needle Time for Intravenous Thrombolysis Is Safer and Improves Outcome in the Czech Republic: Nationwide Study 2004 to 2019Robert Mikulík, Michal Bar, Silvie Bělašková, et al.
Blood|January 15, 2011
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsErik A Nelson, Sarah R Walker, Ellen Weisberg, et al.
Journal of Neurology|March 25, 2011
Decompressive surgery for malignant supratentorial infarction remains underutilized after guideline publicationMichal Bar, Robert Mikulik, David Skoloudik, et al.
Genes & Cancer|December 25, 2012
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsErik A Nelson, Sarah R Walker, Michael Xiang, et al.
Circulation. Cardiovascular Quality and Outcomes|January 31, 2022
Between-Center Variation in Outcome After Endovascular Treatment of Acute Stroke: Analysis of Two Nationwide RegistriesPaula M Janssen, Katrine van Overhagen, Jan Vinklárek, et al.
Neurology. Clinical Practice|August 26, 2024
Utilization, Workflow, and Outcomes of Endovascular Thrombectomy in Patients With vs Without Premorbid Disability in a National RegistryAravind Ganesh, Ondrej Volny, Ingrid Kovacova, et al.
Biomedicines|February 24, 2024
Intravenous Thrombolysis in Posterior versus Anterior Circulation Stroke: Clinical Outcome Differs Only in Patients with Large Vessel OcclusionSimona Halúsková, Roman Herzig, Robert Mikulík, et al.
Hemasphere|March 15, 2021
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid MalignanciesJonathan Feld, Douglas Tremblay, Mikaela Dougherty, et al.
Blood|June 7, 2015
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphomaSalvia Jain, Dina Stroopinsky, Li Yin, et al.
Blood|September 17, 2014
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsRafael Bejar, Allegra Lord, Kristen Stevenson, et al.
Pageof 11